title: Mogoltacin enhances vincristine cytotoxicity in human transitional cell carcinoma (TCC) cell line.
abstract: Bladder cancer is the second common cancer of the genitourinary system throughout the world and intravesical chemotherapy is usually used to reduce tumour recurrence and progression. Human transitional cell carcinoma (TCC) is an epithelial-like adherent cell line originally established from primary bladder carcinoma. Here we report the effect of mogoltacin, a sesquiterpene coumarin from Ferula badrakema on TCC cells. Mogoltacin was isolated from the fruits of F. badrakema, using silica gel column chromatography and preparative thin layer chromatography. Mogoltacin did not have any significant cytotoxicity effect on neoplastic TCC cells at 16, 32, 64, 128, 200 and 600 microg ml(-1) concentrations. In order to analyse its combination effect, TCC cells were cultured in the presence of various combining concentrations of mogoltacin and vincristine. Cells were then observed for morphological changes (by light microscopy) and cytotoxicity using MTT assay. The effect of mogoltacin on vincristine toxicity was studied after 24, 48 and 72 h of drug administration. The results of MTT assay showed that mogoltacin can significantly enhance the cytotoxicity of vincristine and confirmed the morphological observations. Results revealed that combination of 40 microg ml(-1) vincristine with 16 microg ml(-1) mogoltacin increased the cytotoxicity of vincristine after 48 h by 32.8%.
authors: Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.
authors: F
authors: F
authors: Behnam Rassouli
authors: M M
authors: MM
authors: Matin
authors: M
authors: M
authors: Iranshahi
authors: A R
authors: AR
authors: Bahrami
authors: V
authors: V
authors: Neshati
authors: S
authors: S
authors: Mollazadeh
authors: Z
authors: Z
authors: Neshati
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D045744:Cell Line, Tumor; D003374:Coumarins / Q000008:administration & dosage* / Q000494:pharmacology; D004357:Drug Synergism; D005309:Ferula; D005638:Fruit; D006801:Humans; D008517:Phytotherapy; D010936:Plant Extracts / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D012717:Sesquiterpenes / Q000008:administration & dosage* / Q000494:pharmacology; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*; D014750:Vincristine / Q000008:administration & dosage* / Q000494:pharmacology
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D003374:Coumarins; D010936:Plant Extracts; D012717:Sesquiterpenes; C539928:mogoltacin; D014750:Vincristine